Advanced Breast Cancer trials recruiting in Texas

All Advanced Breast Cancer trials nationally

Cities in Texas

Recruiting trials in Texas

• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
  NCT06997029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Fort Worth, San Antonio
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
  NCT07318805 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Conroe, Houston, League City, San Antonio
• A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
  NCT07310420 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: Female · Texas: Houston
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, Irving, San Antonio
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston, San Antonio
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
  NCT06993844 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston, Temple
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  NCT07524322 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio